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Abstract 
Asherman syndrome is a rare acquired clinical condition resulting in the obliteration of the 
uterine cavity due to the presence of partial or complete fibrous intrauterine adhesions 
involving at least two-thirds of the uterine cavity potentially obstructing the internal cervical 
os.  
Common reported symptoms of the disease are alterations of the menstrual pattern with 
decreased menstrual bleeding leading up to amenorrhea and infertility. Hysteroscopy is 
currently considered the gold standard diagnostic and therapeutic approach of patients with 
intrauterine adhesions. However, an integrated approach including preoperative, 
intraoperative and postoperative therapeutic measures are warranted due to the complexity of 
the syndrome. This review aims to summarize the most recent evidence on the recommended 
preoperative, intraoperative and postoperative procedures to restore the uterine cavity and a 
functional endometrium, as well as on the concomitant use of adjuvant therapies to achieve 
optimal fertility outcomes. 
 
Keywords: Asherman's syndrome; Hysteroscopy; Infertility; Intrauterine adhesions; 
Synechiae. 
  
         
 
Introduction 
Asherman syndrome is an acquired condition characterized by the development of obliteration 
of the uterine cavity due to partial or complete fusion of opposing uterine walls by fibrous 
adhesions, also referred as synechiae, leading to menstrual disorders such as amenorrhea or 
decreased menstrual flow, severe cramping pain, and/or subfertility and adverse pregnancy 
outcomes (Yu et al. 2008). Although intrauterine adhesions were first described by Fritsch in 
1894 (Fritsch 1894), Joseph Asherman described the pathophysiology, clinical significance 
and the potential utilization of hysteroscopy for the treatment of intrauterine adhesions in 
1950 and thus it is referred to as Asherman syndrome (Asherman 1950).  
 It is important to clarify that Asherman first described in 1948 a specific type of secondary 
amenorrhea following complicated labor or abortion due to a stenosis or blockage of the 
cervical internal os. Asherman stated that this „amenorrhea traumatica‟ is not functional but 
organic; ovulation continues to occur but the uterus does not react and the endometrium 
remains in a state of inactivity. Hormonal therapy is neither reasonable nor effective, whereas 
simple removal of the blockage is sufficient to restore menstruation to normal (Asherman 
1948). Therefore, the resulting secondary amenorrhea is a form of endometrial deactivation in 
the presence of cervical stenosis with a normal uterine cavity and is not Asherman syndrome 
due to intrauterine adhesions (IUAs). 
Although the cause of IUAs is thought to be associated with vigorous curettage or uterine 
surgery involving the uterine cavity, pelvic infections such as pelvic inflammatory disease 
(PID) as a result of sexually transmitted infections may also lead to Asherman syndrome. 
Other causes of intrauterine infections like tuberculosis or schistosomiasis leading to IUAs are 
particularly important in developing countries. 
Establishing prognostic criteria of this syndrome is challenging as it depends on multiple 
pathophysiologic factors as well as the need to use adequate diagnostic tools to determine the 
         
 
extent of the disease to then establish the appropriate therapy. Once the extent of the condition 
is determined, the next challenge is to plan the appropriate treatment not only to restore the 
intrauterine anatomy and potentially the physiology of the uterine cavity but also to prevent 
recurrence of IUAs to enhance/restore normal reproductive function.  
Preoperative assessment of Asherman syndrome includes the use of transvaginal 
ultrasonography, hysterosalpingography (HSG), saline infusion sonohysterography (SIS) and, 
in particular, hysteroscopy (Schlaff and Hurst 1995, Salle et al. 1999, Reyes-Munoz et al. 
2019). The use of a combination of preoperative, intraoperative and postoperative measures, 
as well as adjuvant therapy to prevent recurrence of IUAs, is generally accepted as the best 
approach to reduce the clinical symptoms, enhance fertility and obtain good reproductive 
outcomes. Such procedures include ultrasound-directed hysteroscopic adhesiolysis, 
mechanical lysis of adhesions to separate the fused uterine walls and the use of adjuvant 
therapy with systemic estrogen with or without progestin administration in conjunction with 
intrauterine barriers and adhesion preventing agents to induce endometrial proliferation (Farhi 
et al. 1993, Zikopoulos et al. 2004). This integrated approach allows to enhance the prognosis 
as well as to prepare the uterine cavity to conceive, especially with those interventions aimed 
to promote endometrial healing.  
This review aims to summarize the most recent evidence on the recommended preoperative, 
intraoperative and postoperative procedures to restore the anatomy of the uterine cavity and a 
functional endometrium, as well as on the use of adjuvant therapies to achieve optimal 
fertility outcomes. 
 
Material and Methods 
The data research was conducted using MEDLINE, EMBASE, Web of Sciences, Scopus, 
ClinicalTrial.gov, OVID and Cochrane Library and querying for all the articles related to 
         
 
Asherman syndrome from the inception of the database up to October 2019. The studies were 
identified with the use of a combination of the following text words: hysteroscopy, 
intrauterine synechiae, Asherman syndrome, infertility. The selection criteria of this narrative 
review included randomized clinical trials, non-randomized controlled studies (observational 
prospective, retrospective cohort studies, case-control studies, case series) and review articles 
of Asherman syndrome in infertile women and the diagnostic and therapeutic role of 
hysteroscopy. A review of articles also included the abstracts of all references retrieved from 
the search. Article not in English language, conference papers and reviews, and studies with 
information overlapping another publication were excluded. In the event of overlapping 
studies, we selected the most recent and/or most comprehensive manuscript.  
 
Preoperative assessment 
Advances in endoscopic technology allow the direct exploration of the uterine cavity and, 
consequently, a more accurate diagnosis and management options of intrauterine pathology. 
Asherman syndrome should be suspected in patients presenting with menstrual changes such 
as decreased menstrual flow, amenorrhea or dysmenorrhea in association with a history of 
infertility, especially in patients with previous curettage or intrauterine surgery. The diagnosis 
is commonly obtained by imaging the uterine cavity with contrast (Hysterosalpingogram). 
However, hysteroscopy is considered the gold standard technique for the evaluation of the 
uterine cavity for the diagnosis of Asherman syndrome (Vitale et al. 2017, Wamsteker K 
1995, De Franciscis et al. 2019).  
It allows direct access and a real-time view of the endometrial cavity, accurately confirming 
the presence, extent, and morphological characteristics of intrauterine adhesions and the 
quality of the endometrium. Besides, it enables an accurate description of the location, degree 
         
 
of the adhesions and classification allowing treatment at the same time “see and treat” (Reyes-
Munoz et al. 2019).  
Hysterosalpingography (HSG) is a cost-effective diagnostic method used to assess tubal 
patency in addition to the size, shape, and contents of the uterine cavity. Before the 
widespread use of hysteroscopy, HSG was the preferred diagnostic modality for Asherman 
syndrome showing contrast filling defects described as homogeneous opacity surrounded by 
sharp edges (Magos 2002). Severe Asherman‟s syndrome is characterized by a completely 
distorted and narrow uterine cavity occluding the uterine ostia. HSG has a diagnostic 
sensitivity of 75-81%, a specificity of 80% and for the diagnosis of IUAs but is a diagnostic 
tool with a high false-positive rate (Positive predictive value 50%) (Yu et al. 2008).  
Transvaginal ultrasound (TVS) is frequently included in the initial evaluation of women with 
gynecologic complaints. Intrauterine adhesions are characterized by an echo-dense pattern 
resulting in difficult identification of the endometrial lining which contains one or more 
translucent "cyst-like" areas (Yu et al. 2008). Although ultrasound has been reported to have 
low diagnostic accuracy (Farhi et al. 1993, Magos 2002, Salle et al. 1999, Zikopoulos et al. 
2004, Soares, Barbosa dos Reis, and Camargos 2000), it allows an adequate mapping of the 
uterine cavity when a complete obstruction of the cervix precludes performing an HSG or 
hysteroscopy.   
The ultrasound scan can also be useful during hysteroscopic adhesiolysis to guide the 
procedure and prevent uterine perforation. Compared to laparoscopic guided adhesiolysis, 
ultrasound-guided adhesiolysis is certainly less invasive and has a lower cost, avoiding 
potential laparoscopic complications with a similar rate of uterine perforation risk (Schlaff 
and Hurst 1995). Moreover, the literature supports ultrasound as a better predictor of the 
surgical repair, because it allows the assessment of residual endometrium: if the residual 
         
 
endometrium after the initial treatment is thin or no endometrium is seen during the 
transvaginal ultrasound, the obstetric outcomes are greatly decreased (Kresowik et al. 2012).  
The role of contrast (saline, gel) infusion sonography or sonohysterography, has also been 
widely investigated. It has a diagnostic sensitivity of 75% and a positive predictive value of 
43%, similar to that reported for HSG. Salle et al. reported the same sensitivity and specificity 
when SHG is compared to the standard HSG (Salle et al. 1999). Recently, a retrospective 
study involving 149 women with intrauterine anomalies, demonstrated a significant difference 
in general accuracy at diagnosing intrauterine pathology favoring SHG. (50.3% in the HSG 
group and 81.8% in the SHG group) (Acholonu et al. 2011).  
To the best of our knowledge, current data about the role of three-dimensional ultrasound 
imaging (3D US) in the diagnosis of intrauterine adhesions are limited (Knopman and 
Copperman 2007). However, 3D US is taking on a growing role in the evaluation of 
intrauterine synechiae, with a sensitivity of 87% and a specificity of 45%, which is higher 
than those obtained with TVS and SHG. Moreover, 3D US and intrauterine saline infusion, 
known as three-dimensional sonohysterography, (3D-SHG) both in combination with or 
without 3D power Doppler (3-DPD) have recently been proposed as a possible imaging 
modality for the diagnosis of intrauterine pathology. However, only low-quality data are 
reported to date on the efficacy of this technique in the diagnosis of intrauterine synechiae 
(Abou-Salem, Elmazny, and El-Sherbiny 2010) and until more robust evidence becomes 
available, the high cost of 3D ultrasound precludes its use in daily clinical practice.  
Magnetic resonance imaging (MRI) represents a supplementary diagnostic tool, especially in 
the case of complete obliteration of the cervical canal. Intrauterine adhesions (IUA) are 
depicted as low signal intensity on T2 weighed-image inside the uterus (Bacelar et al. 1995). 
MRI is generally not necessary and is not used routinely for the diagnosis of Asherman 
syndrome as it is considered not cost-effective as a routine diagnostic tool. 
         
 
Despite the availability of the multiple imaging techniques discussed above, hysteroscopy 
remains the gold standard for the diagnosis and management (assessment and treatment) of 
Asherman‟s syndrome.  
 
Intraoperative assessment 
Lysis of IUAs is considered the gold standard treatment of patients diagnosed with Asherman 
syndrome; nevertheless, there are no RCTs comparing outcomes of surgical intervention 
versus expectant management or between different methods of surgical intervention. Any 
surgical intervention aims to restore as much as possible the anatomy of the endometrial 
cavity and the cervical canal, restoring the normal volume and shape to facilitate the 
communication between the uterine cavity,  the cervical canal and the fallopian tubes; 
subsequently, allowing both normal menstrual flow and adequate sperm transportation for 
fertilization and implantation.  
To date, hysteroscopic adhesiolysis, using a variety of instruments with or without energy, has 
emerged as the gold standard technique for the treatment of intrauterine adhesions allowing 
the so-called, „see and treat‟ approach. Hysteroscopy, reveals important features of 
intrauterine synechiae such as their number, location, extension, structure, and consistency. 
The location of the adhesions can be central or marginal and their extension can be described 
as mild, moderate or severe: in the latter case, only fibrous tissue is seen with small irregular 
endometrial bridges (Nappi and Di Spiezio Sardo 2014, Worldwide 2010). The structure and 
consistency of the adhesions depend on the predominant component that is present (mucosal, 
muscular or fibrous).  
March and Israel introduced a classification based on the extension (mild, moderate and 
severe) of intrauterine synechiae (March, Israel, and March 1978). The American Fertility 
Society (1988) developed a new scoring system for classification of IUAs taking into account 
         
 
the menstrual history as well as hysteroscopic and hysterosalpingographic findings: a 
prognostic classification in 3 stages (stage I: mild; stage II: moderate; stage III: severe) 
resulted. The European Society of Hysteroscopy reported a more detailed classification of 
Asherman syndrome based on the nature and consistency of the adhesions but this 
classification is more cumbersome to use in clinical practice than the former (Wamsteker K 
1995). The most recent classification takes into account the characteristics of intrauterine 
synechiae as well as the gynecologic and obstetric history of the patients: patients have an 
excellent prognosis if a numerical score ranges from 0 to 4 (level 1, mild), while the prognosis 
is considered favorable if the score ranges from 5 to 10 (level 2, moderate) or poor if scoring 
from 11 to 22 (level 3, severe). This classification, however, has been validated only on a 
small number of patients and requires further studies before it is adopted in clinical practice 
(Nasr et al. 2000) (Table 1). 
In the case of mild filmy adhesions, office hysteroscopy without general anesthesia can be 
safely performed allowing the restoration of a normal uterine cavity by breaking the adhesions 
using only the uterine distension pressure and the tip of the hysteroscope (Sugimoto 1978). 
However, more vigorous approaches are required for severe and dense adhesions especially if 
they completely occlude the uterine cavity or if they do not allow the insertion of the 
hysteroscopic sheath inside the cervix. Intuitively, adhesiolysis should be initiated at the 
lowest part of the uterine cavity and advanced upwards as the uterine cavity is being restored 
(Yu et al. 2008). 
The adhesions situated in the central part of the uterine cavity, if filmy and easy to break, 
should be separated first which will allow adequate distension of the uterine cavity. Finally, if 
more dense or lateral adhesions are present, their treatment should be performed at the end of 
the procedure to minimize the risk of bleeding and/or uterine perforation (Deans and Abbott 
2010).  
         
 
It has been reported that even the use of a sharp needle (Touhy needle) for hysteroscopic 
adhesiolysis has a good rate of success in normalizing the menstrual cycle. However, data on 
further fertility after the procedure are not consistent (Broome and Vancaillie 1999). Using 
cold-scissors to break the adhesions is thought to be a superior method because it does not 
cause thermal damage to the residual endometrium. On the other hand, the use of “hot” 
instruments (using energy, electric or laser) may be associated with potential thermal damage 
to the residual endometrial tissue promoting scar formation (Yu et al. 2008, Al-Inany 2001). 
In any case, in the presence of extensive or dense adhesions, the treatment should be 
performed by an expert hysteroscopist using the instruments that he/she is most familiar with. 
 
Prevention of adhesion recurrence 
Following hysteroscopic adhesiolysis, intrauterine devices (IUD), stents, or balloon catheters 
are frequently used to reduce the rate of postoperative adhesion formation, although there is 
limited data regarding the effect on preventing recurrence of IUAs and subsequent fertility 
outcomes when these barriers are used (Aagl Elevating Gynecologic Surgery 2017). 
 
IUD and intrauterine adhesions 
Following hysteroscopic adhesiolysis, the recurrence rate of IUA has been reported to range 
from 3.1% to 23.5% (Valle and Sciarra 1988, Pabuccu et al. 1997). Recurrent adhesions are 
usually thin and filmy (Shokeir, Fawzy, and Tatongy 2008). IUD has been used to prevent 
adhesion recurrence due to the mechanical effect of separating the anterior and posterior 
uterine walls (Conforti et al. 2013) which may help physiological endometrial regeneration. 
Although many authors have reported good results (Ventolini, Zhang, and Gruber 2004, 
Polishuk and Weinstein 1976), data regarding the preferred size and the type of IUD to 
prevent IUAs recurrence are still lacking. Moreover, IUD may induce the release of 
         
 
inflammatory agents which may aggravate endometrial injury delaying healing and 
endometrial regeneration (March 1995). Although it is reported that after the insertion of an 
IUD, a significant number of women regained regular menses (Vesce et al. 2000), the 
levonorgestrel-releasing IUD should be avoided because of its suppressing effect on estrogen 
receptors which are considered necessary for normal regeneration of the endometrium (Deans 
and Abbott 2010). It is important to note that the same rate in adhesion reformation has been 
found among women randomized to receive IUD device, estrogens treatment or no treatment 
after hysteroscopic septum resection (Tonguc et al. 2010). 
Intrauterine balloons  
An intrauterine balloon stent is another mechanical method frequently used to prevent 
the reformation of adhesions following intrauterine adhesiolysis (March 2011). It 
consists of a silicon triangular shape device fitting the uterine cavity (Cook Medical Inc, 
Bloomington, USA). Intrauterine balloon stent can be inserted immediately after the 
procedure with good results in terms of fertility outcome and prevention of adhesions 
recurrence (March 2011, Lin et al. 2013). A prophylactic broad-spectrum antibiotic is 
always recommended for the duration of the stent inside the uterine cavity. 
 
Foley catheters 
A standard pediatric Foley catheter is another commonly used method to prevent the 
recurrence of IUAs following hysteroscopic adhesiolysis (Asherman 1950, March, Israel, and 
March 1978, Ismajovich et al. 1985). In a study involving 25 women with moderate and 
severe adhesions, a fresh amnion graft draped over a Foley catheter balloon inserted into the 
uterus immediately after hysteroscopic lysis of intrauterine adhesions and left inside for two 
weeks showed a significant reduction of adhesion reformation (Amer and Abd-El-Maeboud 
         
 
2006). When compared to IUD, Foley catheter showed a higher conception rate (33.9% 
versus 22.5%), reporting also restoration of normal menstrual pattern in 81% of women 
(Orhue, Aziken, and Igbefoh 2003). Although positive outcomes have been reported, 
randomized controlled trials (RCTs) on the efficacy of Foley catheters in the prevention of 
IUA, are not available. Limits of this approach are mainly the risk of potential uterine 
perforation, ascending infection from the vagina and patient discomfort. 
Hyaluronic acid and other anti-adhesion barriers 
During the last 10 years, hyaluronic acid-derived products have been developed, showing a 
possible role in gynecologic surgery to prevent intra-abdominal and intrauterine adhesions 
(Pellicano et al. 2003, Guida et al. 2004). Hyaluronic acid mechanically inhibits adhesions 
formation due to the temporary formation of a barrier (Reijnen et al. 2000). Autocross-linked 
hyaluronic acid (Hyalobarrier©) is frequently used after gynecological abdominal surgery and 
consists of a viscous gel formed by the autocross-linked condensation of hyaluronic acid, 
preventing intraperitoneal adhesions formation after laparoscopic myomectomy and 
intrauterine adhesions after hysteroscopic procedures (Mais et al. 2012).  
Other anti-adhesion barrier products have been proposed to reduce IUAs recurrences such as 
the one made of chemically modified hyaluronic acid (sodium hyaluronate) and 
carboxymethylcellulose (Seprafilm©) and a newer hyaluronic acid derived (alginate 
carboxymethylcellulose hyaluronic acid). However scientific evidence is still inconsistent to 
allow the recommendation of one product over another. 
 
Bone marrow-derived stem cell (BMDSC)  
The potential to regenerate severely damaged endometrium with human stem cell treatment 
has also been explored with promising results in animal models and humans (Alawadhi et al. 
         
 
2014, Kilic et al. 2014, Kuramoto et al. 2015). In a prospective series by Santamaria et al. 
(Santamaria et al. 2016), 16 women with IUAs confirmed by hysteroscopy were treated with 
uterine intravascular infusions of BMDSC. During the follow-up period, the menstrual 
function returned to normal within 6 months after BMDSC infusion with three spontaneous 
pregnancies and seven pregnancies following in vitro fertilization and embryo transfer (IVF-
ET) reported (Santamaria et al. 2016). 
 
Postoperative management 
One out of three women with Asherman syndrome having mild to moderate IUAs 
(Preutthipan and Linasmita 2003) and two out of three with severe IUAs (Yang et al. 2016) 
have a recurrence of IUA after hysteroscopic adhesiolysis. Obtaining a restored normal 
uterine cavity and a functional endometrial layer are a clinical goal after hysteroscopic 
surgery, especially in women desiring future fertility. According to the AAGL (American 
Association of Gynecologic Laparoscopists) and ESGE (European Society of Gynaecological 
Endoscopy) guidelines, a repeated hysteroscopy is recommended for the follow-up 
assessment of the uterine cavity after treatment of IUAs (Aagl Elevating Gynecologic Surgery 
2017).   
Conventional wisdom dictates that good endometrial healing may be achieved in the presence 
of high estrogen levels. However, there is still not a clear consensus about when exogenous 
hormonal therapy should be initiated, or on the type of regimen, dose, and duration of therapy. 
The latest evidence on hormonal therapy aiming to restore the endometrial thickness is that 
both lower dosage (4 mg) and a higher dose (10 mg) of oestradiol valerate given daily in the 
postoperative period are effective in the reduction of adhesions formation, with better results 
associated with the higher dose. However, both doses allowed a normal restoration of 
         
 
menstrual patterns, but results for fertility outcomes have not yet been reported (Liu et al. 
2019).  
Prolonged preoperative and postoperative treatment with estrogens has been reported in a 
small study including 12 subjects with severe Asherman syndrome. All women resumed a 
normal menstrual pattern and six of them became pregnant (Myers and Hurst 2012). 
Oestradiol valerate 4 mg per day for 4 weeks and medroxyprogesterone acetate (MPA), 10 mg 
per day during the last two weeks of treatment have also been recommended as an ideal 
therapy after surgery for Asherman syndrome (Yu et al. 2008). 
 It has been reported that an estrogen-progestin combination administered after curettage for 
post-partum hemorrhage or incomplete abortion increases the endometrial thickness. 
Specifically, after 21 days of treatment, the transvaginal ultrasound showed a thicker 
endometrium with larger width and volume (Farhi et al. 1993). Also, Tsui et al. proposed 
estrogen treatment (8-10 weeks) after removal of the balloon and second look hysteroscopy. 
Transvaginal ultrasound may be used to asses the endometrial thickness and in-vitro 
fertilization and embryo transfer (IVF-ET) can be performed when the endometrial thickness 
exceeds 5 mm (Tsui et al. 2014).  
Finally, after the failure of hormonal therapy in restoring the endometrium (Nagori, Panchal, 
and Patel 2011), several studies have been conducted during the last ten years exploring new 
horizons including the use of infusing bone marrow derivates or stimulating endometrial 
stromal stem cells. However, data are still inadequate about the effectiveness of stem cells in 
regenerating a physiologically normal endometrial lining and uterine cavity. In this context, 
solid scientific evidence is still needed. 
 
Conclusions 
         
 
Asherman syndrome is a rare pathology secondary to intrauterine adhesion formation that is 
associated with menstrual disorders and reproductive dysfunction. Hysteroscopy is currently 
considered the gold standard for the management because it allows simultaneous diagnosis 
and treatment (“see and treat”). Although there have been significant advances in the 
restoration of the endometrial cavity in the last decade, complete restoration of a normal 
functional endometrial lining has not been achieved. Preliminary evidence suggests a 
promising role of BMDSC in enhancing endometrial healing and reproduction.  However, the 
evidence on the role of BMDSC in clinical practice is still limited and this treatment should 
not be offered outside of rigorous research protocols.  
Finally, a consensus-based adjuvant therapy including the use of intrauterine stents and 
exogenous hormonal therapy aimed to achieve adequate endometrial growth and to prevent 
recurrence of IUAs has not yet been established. Restoration of a functional endometrial 
lining is one of the most important challenges for successful reproductive outcomes. 
Although rare but with great clinical significance, Asherman syndrome requires further basic 
science research work to determine its etiology and potential preventing measures. Well 
designed clinical trials are needed to determine the most appropriate diagnostic and 
therapeutic modalities.  
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Asherman syndrome is a rare pathology secondary to intrauterine adhesion formation 
characterized by menstrual disorders and reproductive dysfunction. Hysteroscopy is currently 
considered the gold standard for the management because it allows simultaneous diagnosis 
and treatment. Asherman syndrome requires further basic science research to determine its 
etiology and potential preventing measures. 
 
  
         
 
Table 1. Summary of the three main classification systems of intrauterine adhesions (IUA) 
 
Authors (year of 
publication) 
Classification 




Classification system including the extent of uterine cavity involved (<1/3, 1/3-2/3, 
>2/3) and the type of IUAs (filmy, filmy-dense, dense) as well as the menstrual 
pattern (normal, hypomenorrhea and amenorrhea) 
Stage I: mild (score 1-4) 
Stage II: moderate (score 5-8) 
Stage III: severe (score 9-12) 
European Society for 
Hysteroscopy (1995) 
Six types (I-VI) of IUA classified as following: 
Type I: subtle or velamentous IUA 
Type II: single fibrous synechiae 
Type IIa: obliterating isthmic synechiae in presence of normal uterine cavity 
Tipe III: multiple fibrous synechiae with frequent obliteration of one of the tubal 
ostium 
Type IIIa: wide involvement of uterine walls 
Type IIIb: combination of types III and IIIb 
Type IV: Fusion of the uterine cavity due to extensive fibrous synechiae, with 
frequent obliteration of both tubal ostium 
Nasr et al. (2000) Classification system including the characteristics of IUA as well as the 
gynecologic and obstetric history of the patient (isthmic synechia, viscous 
synechia, dense synechia, tubal ostia, menstrual pattern and reproductive 
anamnesis). 
Excellent prognosis: total score 0-4 (grade 1, mild) 
Favorable prognosis: total score 5-10 (grade 2, moderate) 
Severe prognosis: total score 11-20 (grade 3, severe) 
         
